Soy protein infant formulae and follow-on formulae: A commentary by the ESPGHAN Committee on Nutrition
Soy protein infant formulae and follow-on formulae: A commentary by the ESPGHAN Committee on Nutrition
复制标题
DOI：
10.1097/01.mpg.0000189358.38427.cd
复制
发表时间：
2006-04-01
影响因子：
2.9
通讯作者：
Turck, D
中科院分区：
文献类型：
--
作者：
Agostoni, C;Agostoni, C;Turck, D
欧洲小儿胃肠病学肝病学和营养学会 (ESPGRAN) 营养委员会的评论总结了有关大豆蛋白配方奶粉作为母乳喂养和牛奶蛋白配方奶粉替代品的成分和用途的现有信息，以及它们支持婴儿充分生长和发育的适用性和安全性。大豆是一种不如牛奶的蛋白质来源，消化率和生物利用度较低，蛋氨酸含量也较低。对于大豆蛋白婴儿配方奶粉，只能使用分离蛋白，欧盟现行法规要求的最低蛋白质含量高于牛奶蛋白婴儿配方奶粉（2.25 g/100 kcal vs. 1.8 g/100 kcal）。大豆蛋白配方奶粉可用于喂养足月婴儿，但它们与牛奶蛋白配方奶粉相比没有营养优势，并且含有高浓度的植酸盐、铝和植物雌激素（异黄酮），可能会产生不良影响。没有数据支持早产儿使用大豆蛋白配方奶粉。大豆蛋白配方奶粉的适应症包括严重持续性乳糖不耐受、半乳糖血症和伦理考虑（例如纯素食概念）。大豆蛋白配方奶粉对预防过敏性疾病没有作用，因此不应用于出生后 6 个月内有食物过敏的婴儿。如果考虑使用大豆蛋白配方食品治疗 6 个月后的食物过敏，因为其成本较低且接受度较高，则应首先通过临床试验确定对大豆蛋白的耐受性。没有证据支持使用大豆蛋白配方来预防或治疗婴儿绞痛、反流或长时间哭泣。
This comment by the European Society for Paecliatric Gastroenterology Hepatology and Nutrition (ESPGRAN) Committee on Nutrition summarizes available information on the composition and use of soy protein formulae as substitutes for breastfeeding and cows' milk protein formulae as well as on their suitability and safety for supporting adequate growth and development in infants. Soy is a source of protein that is inferior to cows' milk, with a lower digestibility and bioavailability as well as a lower methionine content. For soy protein infant formulae, only protein isolates can be used, and minimurn protein content required in the current European Union legislation is higher than that of cows' milk protein infant formulae (2.25 g/100 kcal vs. 1.8 g/100 kcal). Soy protein formulae can be used for feeding term infants, but they have no nutritional advantage over cows' milk protein formulae and contain high concentrations of phytate, aluminum, and phytoestrogens (isoflavones), which might have untoward effects. There are no data to support the use of soy protein formulae in preterm infants. Indications for soy protein formulae include severe persistent lactose intolerance, galactosermia, and ethical considerations (e.g., vegan concepts). Soy protein formulae have no role in the prevention of allergic diseases and should not be used in infants with food allergy during the first 6 months of life. If soy protein formulae are considered for therapeutic use in food allergy after the age of 6 months because of their lower cost and better acceptance, tolerance to soy protein should first be established by clinical challenge. There is no evidence supporting the use of soy protein formulae for the prevention or management of infantile colic, regurgitation, or prolonged crying.